- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02507154
Reactivating NK Cells in Treating Refractory Head and Neck Cancer (NKEXPHNC)
Phase I/II Study of Expanded, Activated Autologous Natural Killer Cell Infusions With Cetuximab for Patients With EGFR-Positive Nasopharyngeal Carcinoma or Head and Neck Squamous Cell Carcinoma
Study Overview
Status
Intervention / Treatment
Detailed Description
Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system that are responsible for direct and indirect cytolytic killing of virally-transformed and/or cancer cells. Harnessing NK cells in cancer immunotherapy therefore, provides a direct cytotoxic effect on cancer cells which further stimulates further downstream adaptive anti-tumor immune responses against the cancer. In order to effect a more targeted killing of these tumor cells, using a monoclonal antibody (mAb) to direct these NK cells to the target site is feasible, provided a specific tumor antigen can be identified. In nasopharyngeal Carcinoma (NPC) and head and neck squamous cell carcinoma (HNSCC) where epidermal growth factor receptor (EGFR) is ubiquitously expressed, combining NK cell therapy with cetuximab (a chimeric mouse/human anti-EGFR monoclonal antibody) to direct these NK cells against these EGFR tumor targets is possible. In this study, we seek to enhance the antitumor activity of cetuximab to treat EGFR-positive head and neck cancers by combing infusion of activated expanded autologous NK cells with cetuximab. Patients selected for this trial are those with refractory NPC and HNSCC where no feasible therapeutic options are available. This is a lead-in phase I followed by a phase II study. The phase I study will enroll 9 patients and will test the feasibility and safety of this combination strategy and determine the tolerated dose of NK cell infusion (1x1^06/kg or 1x10^7/kg NK cells) in adult EGFR positive NPC and HNSCC patients. For the first 3 patients, each new patient will only be enrolled at least 3 weeks after treatment of the preceding patient to allow sufficient time to monitor toxicities. Initial phase of treatment consists of 7 weeks of cetuximab monotherapy. At week 8, clinical evaluation will be done to determine patients who are suitable to continue this study with NK cell therapy, based on the severity of toxicities encountered. Eligible patients will undergo apheresis (Day -10) to harvest NK cells. The collected NK cells will be expanded and activated in the laboratory. During cycle 1, cetuximab will be given on day 1 with subcutaneous IL-2 (three times per week for 2 weeks); followed by expanded NK cells on day 2. The purpose of IL-2 is to sustain activity of these NK cells in-vivo. Cetuximab will be administered weekly for additional 2 weeks following the NK cell infusion during cycle 1. For cycle 2 and 3, cetuximab monotherapy will be administered every 21 days. Clinical evaluation will be performed upon completion of cycle 3. Patients with stable disease or with partial response will be allowed to continue with a second NK infusion dose as per cycle 1, followed by additional 2 more cycles of cetuximab monotherapy (every 21 days).
.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Chwee Ming Lim, MBBS
- Phone Number: 6772 2631
- Email: chwee_ming_lim@nuhs.edu.sg
Study Locations
-
-
-
Singapore, Singapore, 119228
- Recruiting
- National University Hospital
-
Contact:
- Chwee Ming Lim, MBBS
- Phone Number: 6772 2631
- Email: chwee_ming_lim@nuhs.edu.sg
-
Contact:
- Serene CH Siow
- Phone Number: 6772 3850
- Email: chor_hiang_siow@nuhs.edu.sg
-
Principal Investigator:
- Chwee Ming Lim, MBBS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Age >21
- Histologically confirmed diagnosis of EGFR-positive nasopharyngeal carcinoma or EGFR positive HNSCC (based on >80% immunohistochemistry of biopsy of recurrent tumor Ventana (Roche) clone 3C6
- Recurrent cancer that is not surgically salvageable
- Metastatic disease (after one course of palliative chemotherapy has been completed)
- Presence of measurable tumor by RECIST 1.1 criteria
- At least two weeks since receipt of any biological therapy, chemotherapy, and/or radiation
- Adequate organ function
- Haemoglobin ≥ 9g/dL ANC ≥ 1500/µL Platelet count ≥ 100,000/µL Creatinine clearance ≥60ml/minute Total bilirubin ≤ 1.5 x upper limit normal (ULN) AST ≤ 5 x upper limit normal ALT ≤ 2 x upper limit normal INR and PTT <1.5 x upper limit normal (ULN)
- ECOG performance status of 0-2
- Life expectancy of at least 60 days
- Localized radiotherapy for palliative pain management is permissible
- Written consent to participate on study
- Physiological dose of steroid replacement is permissible
Exclusion Criteria
- Treatment within the last 30 days with any investigational drug
- Hypersensitivity to cetuximab or any excipients of the NK cell product
- Concurrent administration of any other tumor therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy
- Major surgery within 28 days of study drug administration
- Radiotherapy to the target lesions during study or within 3 weeks prior to study treatment.
- Autologous bone marrow transplant
- Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy
- Lactating or pregnant
- Unwilling to use adequate barrier contraception measures during study period.
- Second primary malignancy that is clinically detectable at the time of consideration for study enrolment
- Receipt of immunosuppressives or steroids (=1mg/kg) during time period of 3 days prior to expanded NK cell infusion to 30 days after infusion (i.e. day -3 to day +30).
- Symptomatic brain metastases
- Electrocardiogram with clinically significant findings.
Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator; serious cardiac illness or medical conditions including but not limited to:
- Patients with dyspnea at rest.
- History of documented congestive heart failure
- High risk uncontrolled arrhythmias
- Angina pectoris requiring a medicinal product
- Clinically significant valvular disease
- Poorly controlled hypertension
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cetuximab + NK cells
During cycle 1, patient will receive intravenous cetuximab and subcutaneous IL-2 on day 1, followed by NK cell infusion on day 2, with subcutaneous IL-2 for an additional 5 doses three times a week to support NK cell viability and expansion in vivo.
Following NK cell infusion, cetuximab will be administered weekly for another 2 weeks.
During cycle 2 and 3, one cycle of cetuximab monotherapy will be administered 3 weeks apart.
Patients who demonstrate objective tumor response or stable disease after cycle 3 will receive a second infusion of NK cells along with cetuximab during cycle 4 therapy at the same dose and schedule as in cycle 1.
This will be followed by 2 additional cycles of cetuximab monotherapy (3 weeks apart).
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as measured by clinical examination including hematology, renal and liver function tests, adverse events and any significant biochemical abnormalities or toxicities
Time Frame: 12- 18 weeks
|
During cycle 1 (21 days) and for at least 21 days following a second NK cell infusion if administered, patients will be reviewed twice a week. Clinical examination including hematology, renal and liver function tests will be performed. Any adverse events (using NCI CTC grading) and concomitant medications notation will be recorded. Any significant biochemical abnormalities or toxicities will be monitored till resolution of these findings or 30 days after patient withdraws from this study, whichever occurs later. During cycles with cetuximab monotherapy, patients with be reviewed once every cycle (21 days). |
12- 18 weeks
|
Objective tumor response
Time Frame: Up to 24 months
|
In this study, treatment response will be determined using RECIST 1.1 criteria, after two and four cycles of therapy.
The endpoints of the study are objective tumor response including overall response rate (ORR), partial response (PR), duration of complete response (DCR) and duration of partial response (DPR).
Complete response is defined by complete resolution of target lesion while partial response is defined by reduction of the target lesion by at least 20% from its baseline.
Duration of tumor response will be censored at the date of the last follow-up visit for tumor responders who are still alive and who have not progressed.
|
Up to 24 months
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Neoplasms, Squamous Cell
- Carcinoma
- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Cetuximab
Other Study ID Numbers
- NK0906
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nasopharyngeal Cancer
-
Stanford UniversityTerminatedStage IV Nasopharyngeal Carcinoma | Stage III Nasopharyngeal Carcinoma | Stage IVA Nasopharyngeal Carcinoma | Stage IVB Nasopharyngeal Carcinoma | Stage II Nasopharyngeal Carcinoma | Stage 0 Nasopharyngeal Carcinoma | Stage 0 Paranasal Sinus Cancer | Stage I Nasopharyngeal Carcinoma | Stage I Paranasal... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Nasopharyngeal Cancer | Stage IV Nasopharyngeal CancerUnited States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingMetastatic Nasopharyngeal CancerChina
-
National Cancer Centre, SingaporeNovartis; Advanced Accelerator ApplicationsRecruitingMetastatic Nasopharyngeal CancerSingapore
-
National University Hospital, SingaporeMerck Sharp & Dohme LLCNot yet recruitingMetastatic Nasopharyngeal Cancer | Locally Recurrent CancerSingapore
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedMetastatic Nasopharyngeal CancerChina
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; First People's Hospital... and other collaboratorsRecruitingNasopharyngeal Carcinoma | Endoscopic Surgery | Primary Napharyngeal Carcinama | Stage I Nasopharyngeal CancerChina
-
National University Hospital, SingaporeUnknownNasopharyngeal Cancer | Colorectal CancerSingapore
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRecurrent / Metastatic Nasopharyngeal CancerChina
-
Universiti Kebangsaan Malaysia Medical CentreCompletedXerostomia, Hyposalivation, Saliva Substitute, Radiation-induced Toxicity, Nasopharyngeal CancerMalaysia
Clinical Trials on Cetuximab + NK cells
-
Chongqing Public Health Medical CenterZhejiang Qixin Biotech; Chongqing Sidemu BiotechUnknown
-
Asclepius Technology Company Group (Suzhou) Co....UnknownPancreatic CancerChina
-
Hangzhou Cheetah Cell Therapeutics Co., LtdTerminatedSafety and EfficacyChina
-
Asclepius Technology Company Group (Suzhou) Co....UnknownMalignant TumorChina
-
Nationwide Children's HospitalNot yet recruitingHigh Grade GliomaUnited States
-
Xinxiang medical universityFirst Affiliated Hospital of Xinjiang Medical UniversityCompleted
-
jiuwei cuiUnknownSmall Cell Lung CancerChina
-
Instituto de Investigación Hospital Universitario...Recruiting
-
The Second Affiliated Hospital of Fujian Medical...Shanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaUnknown
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownAdult Acute Myeloid Leukemia in RemissionItaly